India Pesticides Ltd Q2 FY2027 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/i9jr3548fasw2j89wd4p6k23.pdf

Key Takeaways


Revenue: The H1 Miss and the H2 Bet

D.K. Jain: "Sir, whatever we are lagging in half year, at least we want to cover this up in the coming 6 months."

Margins: Compressed but Defended

D.K. Jain: "We are quite confident that we should be able to maintain the EBITDA margin what we have achieved in this quarter."

Registration-Led Market Access


Hamirpur Subsidiary: Live but Under Review

D.K. Jain: "Because of the geopolitical situation, some of the raw materials availability has become difficult. Some prices have fluctuated a lot and the demand pattern is also changing. So considering all these aspects, we are revisiting the complete portfolio what we have planned, especially for our subsidiary."

Backward Integration: The Quiet Margin Story


Guidance & Commitments

CommitmentSpecificsTimeline
Full-year revenueAt least match FY26 revenue (₹295 cr in Q2 FY26; full-year figure not restated)FY27
H2 revenueSimilar to or slightly better than H2 FY26 to partially compensate for H1 shortfallH2 FY27
EBITDA marginMaintain Q2 FY27 level (14.4%)Ongoing
Subsidiary turnover₹40–50 croresH2 FY27
Subsidiary next-year revenueAt least ₹80 crores additional revenue on ~₹40 crores incremental capexFY28
Argentina first-year revenue₹20–25 crores from the single registered moleculeFirst year (undated start)
Inventory normalizationNormalize by Q4 FY27, supported by good Q3 inquiries for rice herbicideQ4 FY27
Hamirpur block expansionTwo more blocks operational"Most probably next year"
Capex (IPL standalone)₹40–45 croresFY27
Capex (subsidiary)₹80–90 crores; second phase being revisited, funded as need arisesFY27

Key Metrics

MetricQ2 FY27
Revenue₹231 cr, -22% YoY from ₹295 cr in Q2 FY26
EBITDA₹33 cr, margin of 14.4% vs ₹54 cr and 18.2% in Q2 FY26
Profit after tax₹18 cr, margin of 8% vs ₹32 cr in Q2 FY26
Revenue from technicals and API₹115 cr
Formulation revenue₹111 cr, up from ₹72 cr in Q1 FY27, one of the highest in several quarters
H1 FY27 revenue₹487 cr, -15.9% YoY from ₹579 cr in H1 FY26
H1 FY27 EBITDA₹73 cr, margin of 14.9% vs ₹108 cr and 18.6% in H1 FY26
H1 FY27 PAT₹41 cr, margin of 8.5% vs ₹67 cr and PAT margin of 8.5% in H1 FY26
H1 FY27 export revenue₹177 cr vs ₹229 cr in H1 FY26
H1 FY27 operating cash flow₹48 cr
Net cash (consolidated)₹36 cr as on 30 Sep 2026, up from ₹29 cr as at March end
Gross margin~50%, better YoY; adjusted for incremental job work charges would be lower by 3 ppt but still higher YoY due to product mix
Job work charges~₹12 cr vs ~₹6 cr in Q2 FY26, included in other expenses
Export orders on hand~₹100 cr from Europe and Australia, partially executed, partly to be executed in coming months
Backward integration~75% of products backward integrated
Raw material sourcing>65% from India, ~20% from China, remainder from other countries
Installed capacity (technicals)28,300 MT across Dewa Road and Sandila; Hamirpur permitted capacity 30,000 MT
Installed capacity (formulations)10,200 MT across Dewa Road and Sandila; Hamirpur permitted capacity 6,000 MT
Hamirpur blocks operational2 of 10 blocks operational, 2 additional blocks expected operational early next year
Subsidiary capitalization~₹65 cr in September 2026, expected H2 FY27 turnover of ₹40–50 cr from subsidiary
Capex guidance (standalone)₹40–45 cr, on track
Capex guidance (subsidiary)₹80–90 cr, second phase being revisited, short of earlier ₹120–130 cr guidance
Argentina new market anticipation₹20–25 cr first-year business from a single molecule
Sales network18 states, 24 depots, 6 zonal offices, ~405 sales personnel
R&D2 DSIR-recognized centers, 25 scientists